Study of T-PRED(TM) Compared to Pred Forte(R)

Phase 2

Completed

• Conditions: Cataract
• Interventions: Drug: T-PRED; Drug: Pred Forte

• Registration Number: NCT00699803
• Lead Sponsor: Bausch & Lomb Incorporated

Brief Summary

Study of T-PRED(TM) compared to Pred Forte(R)

Detailed Description

Not available

Study Timeline

• Study Start: 2008-05
• Study First Submitted: 2008-06-16
• Study First Submitted QC: 2008-06-17
• Study First Posted: 2008-06-18
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Disposition First Submitted: 2011-09-02
• Disposition First Submitted QC: 2011-09-02
• Disposition First Posted: 2011-09-12
• Results First Submitted: 2020-08-18
• Results First Submitted QC: 2020-08-18
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-02
• Results First Posted: 2020-09-03
• Last Update Posted: 2020-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• 18 years of age

Exclusion Criteria

• No active or adverse disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
T-Pred	T-PRED	Tobramycin prednisolone acetate combination
Pred Forte	Pred Forte	Prednisolone acetate

Primary Outcome Measures

Name	Time	Method
Mean Aqueous Humor Prednisolone Acetate Concentration	4 hours

Trial Locations

Locations (1)

ISTA Pharmaceuticals, Inc.; 🇺🇸 Irvine, California, United States